A systematic qualitative review of ethical issues in open label placebo in published research
- PMID: 40210672
- PMCID: PMC11986115
- DOI: 10.1038/s41598-025-96425-5
A systematic qualitative review of ethical issues in open label placebo in published research
Abstract
Open-label placebos (OLPs), which are transparently administered inert treatments, have gained increasing attention in the research community. They have the potential to harness placebo effects without deceiving the patient. The purpose of this study was to examine and synthesize prior research discussing ethical issues in OLPs. A systematic qualitative literature review was conducted (last search on January 2023) across multiple databases (e.g., MEDLINE, Embase, PsycInfo) using keywords related to OLPs. Publications were screened and assessed for eligibility. Seventeen articles explicitly addressing OLP ethics were included. Data were extracted and thematically analyzed following established qualitative content analysis procedures. 37 distinct ethical issues were identified, grouped into five overarching themes: (1) Sociocultural and Contextual Factors, (2) Implementation and Logistics, (3) Informed Consent, (4) Patient Health Behavior and Dynamics, and (5) Therapeutic Relationship. Frequently mentioned concerns focused on uncertainty of OLP efficacy, the need for further research, and complexities of dose-extending OLPs. The effective integration of OLPs into healthcare necessitates thoughtful consideration and responsible communication. This analysis shows that demonstrating the efficacy of OLPs becomes pivotal for their widespread adoption, underscoring the necessity for additional research to validate their effectiveness. This review was pre-registered on January 26th, 2023, in the Open Science Framework Registry under the identifier: DOI https://doi.org/10.17605/OSF.IO/R6NKG .
Keywords: Bioethics; OLP; Open label placebos; Placebo research; Systematic qualitative review.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethical approval and informed consent: This article does not contain any studies with human participants performed by any of the authors.
Similar articles
-
Treating Pain With Open-Label Placebos: A Qualitative Study With Post-Surgical Pain Patients.J Pain. 2021 Nov;22(11):1518-1529. doi: 10.1016/j.jpain.2021.05.001. Epub 2021 May 15. J Pain. 2021. PMID: 34004348 Free PMC article.
-
Primary care providers' use of and attitudes towards placebos: An exploratory focus group study with US physicians.Br J Health Psychol. 2020 Sep;25(3):596-614. doi: 10.1111/bjhp.12429. Epub 2020 May 30. Br J Health Psychol. 2020. PMID: 32472982 Free PMC article.
-
More than consent for ethical open-label placebo research.J Med Ethics. 2020 Sep 3:medethics-2019-105893. doi: 10.1136/medethics-2019-105893. Online ahead of print. J Med Ethics. 2020. PMID: 32883709
-
Effects of open-label placebos in clinical trials: a systematic review and meta-analysis.Sci Rep. 2021 Feb 16;11(1):3855. doi: 10.1038/s41598-021-83148-6. Sci Rep. 2021. PMID: 33594150 Free PMC article.
-
Placebos Without Deception: Outcomes, Mechanisms, and Ethics.Int Rev Neurobiol. 2018;138:219-240. doi: 10.1016/bs.irn.2018.01.005. Epub 2018 Apr 4. Int Rev Neurobiol. 2018. PMID: 29681327 Free PMC article. Review.
References
-
- Bartley, H., Clarke, S. & Ryan, C. Ethical frameworks for the use of placebos in clinical practice: a scoping review. BMC Med. Ethics22, 56. 10.1186/s12910-021-00631-9 (2021). - PubMed
-
- Foddy, B. A duty to deceive: placebos in clinical practice. Am. J. Bioethics9, 4–12. 10.1080/15265160903318350 (2009). - PubMed
-
- Miller, F. G. & Colloca, L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am. J. Bioethics9, 39–47. 10.1080/15265160903316263 (2009). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources